EGFR and colorectal carcinoma: We further hypothesized that the pharmacodynamics effects of SYM004, with sustained decrease in EGFR expression and with the effective blockade of ligand–receptor interaction together with receptor down modulation, may explain the antiproliferative activity of SYM004 in cetuximab-resistant CRC models.